Concepedia

Author

Mark Ayers

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

M A AYERS, M Ayers, M. Ayers, Mark A Ayers, Mark Ayers

106

Publications

15.6K

Citations

40

H-Index

61

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)The University of Texas MD Anderson Cancer CenterUniversity of ChicagoDana-Farber Cancer InstituteFox Chase Cancer Center
MA

About

Mark Ayers is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

21

25

5.7K

2

Health Sciences

4

4

180

3

Biostatistics

3

3

171

4

Engineering

1

1

11

5

Public Health

1

1

50

Mark Ayers

×

46

Publications

14.6K

Citations

37

H-Index

YearCitations

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Mark Ayers, Jared Lunceford, Michael Nebozhyn,

Journal of Clinical Investigation

2017

3.7K

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Răzvan Cristescu, Robin Mogg, Mark Ayers,

Science

2018

2.3K

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

Răzvan Cristescu, Jeeyun Lee, Michael Nebozhyn,

Nature Medicine

2015

2.2K

Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

Roman Rouzier, Charles M. Perou, W. Fraser Symmans,

Clinical Cancer Research

2005

1.9K

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Patrick A. Ott, Yung‐Jue Bang, Sarina A. Piha‐Paul,

Journal of Clinical Oncology

2018

965

Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer

Mark Ayers, W. Fraser Symmans, James Stec,

Journal of Clinical Oncology

2004

566

Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer

Roman Rouzier, Radhika Rajan, Peter J. Wagner,

Proceedings of the National Academy of Sciences

2005

407

Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.

Lajos Pusztai, Mark Ayers, James Stec,

PubMed

2003

234

Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma

Hung Huynh, Van Chanh Ngo, Joseph Fargnoli,

Clinical Cancer Research

2008

220

Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.

Antoni Ribas, Caroline Robert, F. Stephen Hodi,

Journal of Clinical Oncology

2015

198

Page 1